A biorelevant in vitro release/permeation system for oral transmucosal dosage forms

Int J Pharm. 2012 Jul 1;430(1-2):104-13. doi: 10.1016/j.ijpharm.2012.03.050. Epub 2012 Apr 3.

Abstract

This research describes the development and validation of a biorelevant in vitro release/permeation system to predict the in vivo performance of oral transmucosal dosage forms. The system is a biorelevant bidirectional transmucosal apparatus which allows better simulation of oral cavity physiological variables in comparison to compendial dissolution apparatuses and therefore may be a better predictor of in vivo behavior. The feasibility of the bidirectional apparatus was studied using smokeless tobacco (snus) as a model oral transmucosal product. In this research, nicotine release and permeation was investigated from commercially available snus using a modified USP IV flow-through apparatus, a commercially available vertical diffusion cell and a fabricated novel bidirectional transmucosal apparatus. The percent nicotine released/permeated was utilized as an input function for the prediction of in vivo plasma nicotine profiles by back calculation based on the Wagner-Nelson method. The prediction errors in C(max) and AUC(0-∞) with the USP IV flow-through device, vertical diffusion cell and novel apparatus were 4.03, 22.85 and 1.59 and -5.85, 5.85 and -9.27% respectively. This work demonstrated the suitability of the novel bidirectional transmucosal apparatus for predicting the in vivo behavior of oral transmucosal products.

Publication types

  • Comparative Study
  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Administration, Buccal
  • Adsorption
  • Adult
  • Area Under Curve
  • Chemistry, Pharmaceutical
  • Chromatography, High Pressure Liquid
  • Diffusion
  • Dosage Forms
  • Drug Compounding
  • Equipment Design
  • Feasibility Studies
  • Humans
  • Membranes, Artificial*
  • Models, Biological
  • Mouth Mucosa / metabolism*
  • Nicotine / administration & dosage
  • Nicotine / blood
  • Nicotine / metabolism*
  • Nicotine / pharmacokinetics
  • Nicotinic Agonists / administration & dosage
  • Nicotinic Agonists / blood
  • Nicotinic Agonists / metabolism*
  • Nicotinic Agonists / pharmacokinetics
  • Permeability
  • Reproducibility of Results
  • Saliva / metabolism
  • Solubility
  • Technology, Pharmaceutical / instrumentation*
  • Technology, Pharmaceutical / methods
  • Tobacco, Smokeless / metabolism*
  • Tobacco, Smokeless / pharmacokinetics

Substances

  • Dosage Forms
  • Membranes, Artificial
  • Nicotinic Agonists
  • Nicotine